How Cardiovascular Health Shapes Lifespan: What the Evidence Shows

Living longer is not just about dodging disease—it is about keeping the heart and blood vessels young. A sweeping narrative review published in Frontiers in Cardiovascular Medicine synthesizes evidence across genetics, metabolism, lifestyle, and environment to answer a deceptively simple question: how much of human longevity runs through the cardiovascular system? The authors, led by Amith Seri and Chayakrit Krittanawong, argue that cardiovascular health is a key determinant not only of lifespan but of the quality of aging itself, and they draw unusually careful lines between what the evidence actually proves and what remains an intriguing hypothesis.

The review anchors its analysis in the American Heart Association’s Life’s Essential 8 framework, which scores eight metrics—diet, physical activity, nicotine avoidance, sleep health, body mass index, blood lipids, blood glucose, and blood pressure—each from 0 to 100. The numbers are striking. In a nationally representative sample of 23,003 US adults, people with high cardiovascular health scores had a life expectancy at age 50 of 36.2 years, compared with just 27.3 years for those with low scores—an 8.9-year gap, roughly 43% of which is attributable to lower cardiovascular mortality. The association persists into extreme old age: in a combined analysis of the China Kadoorie Biobank and the China Hainan Centenarian Cohort covering 31,473 adults aged 30 to 116, higher cardiovascular health was linked to lower all-cause mortality at every life stage, including a 54.8% lower risk among centenarians, with physical activity and body mass emerging as the most influential components in that group.

Genetics supplies the first thread connecting heart health to longevity. Twin and pedigree studies estimate that heritable factors account for 10% to 30% of lifespan variation. The apolipoprotein E gene stands out: French centenarians show depletion of the APOE ε4 variant—which raises LDL cholesterol and the risk of both coronary artery disease and Alzheimer’s disease—and enrichment of the generally protective ε2 variant, a pattern the authors attribute to long-term survival selection driven primarily by cardiovascular risk. A second recurring locus is FOXO3. In a 17-year prospective study of older American men of Japanese ancestry, validated in white and Black populations, carriage of the longevity-associated G allele of rs2802292 was associated with a 10% reduction in all-cause mortality, driven mainly by a 26% lower risk of death from coronary heart disease. Carriers also showed lower plasma tumor necrosis factor-α and protection against telomere shortening, suggesting the gene acts through redox defense, telomere preservation, and inflammatory regulation. Notably, the protection appears conditional: in the Kuakini Honolulu Heart Program, the G allele lowered coronary risk only in hypertensive men, buffering cardiovascular stress rather than reducing baseline risk.

Beneath these genes lie shared biological mechanisms. The review identifies five recurring processes—oxidative stress, chronic low-grade inflammation, metabolic disturbance, vascular change, and genetic-epigenetic regulation—that simultaneously drive cardiovascular aging and shape lifespan. Oxidative stress, an imbalance between reactive oxygen species and antioxidant defenses, damages mitochondrial DNA and activates senescence pathways. In mice engineered to inhibit the type 5 isoform of adenylyl cyclase, a component of β-adrenergic signaling, increased superoxide dismutase levels conferred resistance to stress-induced cardiomyopathy and extended lifespan by nearly 30%. The concept of mitohormesis—where mild ROS exposure triggers adaptive stress resistance—adds nuance, suggesting that not all oxidative signaling is harmful.

Inflammation may be the most clinically mature mechanism. Persistent oxidative stress activates the redox-sensitive transcription factor NF-κB, sustaining the senescence-associated secretory phenotype and the smoldering, low-level inflammation known as inflammaging. Elevated interleukin-1, IL-6, tumor necrosis factor-α, and C-reactive protein track with cardiovascular disease and death, while anti-inflammatory cytokines such as IL-10 are associated with exceptional longevity. The randomized canakinumab trial, which blocks IL-1β, confirmed a causal role for inflammation in cardiovascular events—though it did not test lifespan extension, and survival benefits from NF-κB inhibition have so far been demonstrated only in fruit flies. Metabolic dysfunction reinforces the loop: hyperglycemia accelerates aging through advanced glycation end products, while excessive insulin/IGF-1 signaling suppresses longevity-promoting pathways such as AMPK, FOXO, and sirtuins and activates mTOR, a major driver of cellular aging.

Here the review delivers its most sobering caveat. The celebrated longevity pathways—mTOR inhibition, sirtuin activation, insulin/IGF-1 signaling—extend lifespan consistently in worms, flies, and mice, but no human trial has ever demonstrated lifespan extension through these routes. Statin therapy, which targets HMG-CoA reductase, is standard clinical care for cardiovascular risk, yet the large PROSPER trial did not show a lifespan benefit in older adults. Calorie restriction improves human cardiometabolic risk factors, but a direct life-extending effect remains unproven in people. Vascular changes tell a different story: arterial stiffness, measured by carotid–femoral pulse wave velocity, independently predicts cardiovascular events and mortality, and familial longevity has been linked to lower stiffness in offspring. The IKARIA study found that adults over 50 on the Greek island had significantly lower pulse wave velocity than age-matched general populations, hinting at decelerated vascular aging shaped by genetics, environment, and lifestyle together.

The review also confronts the contested obesity paradox—the observation that overweight or obese patients with cardiovascular disease sometimes show better short- to mid-term survival than normal-weight peers. The authors attribute much of this pattern to measurement limitations: body mass index alone cannot distinguish visceral fat, fat distribution, or lean muscle mass, and confounding by smoking, which lowers weight but raises mortality, can artificially flatter higher-BMI groups. Analyses using refined measures such as the Visceral Adiposity Index reveal non-linear, J-shaped relationships with mortality, suggesting fat distribution and quality matter more in older adults than BMI. Obesity and aging share biological pathways—mitochondrial dysfunction, chronic inflammation, impaired autophagy, and cellular senescence—so resolving the paradox will require body-composition-based research rather than reliance on a single number.

On the intervention side, diet emerges as the most actionable lever. In large US prospective cohorts followed for roughly 30 years, adherence to the Alternative Healthy Eating Index, the Alternative Mediterranean Index, DASH, and MIND diets was consistently linked to higher odds of healthy aging—surviving to old age free of major chronic disease while maintaining independence—and the AHEI showed the strongest association among eight dietary scores tested. Higher intake of ultra-processed foods independently reduced the odds of healthy aging. The gut microbiome provides a mechanistic bridge: microbial metabolism of dietary choline and L-carnitine generates trimethylamine N-oxide, or TMAO, which large clinical studies have confirmed as a predictor of cardiovascular disease. In a randomized crossover feeding trial, a Mediterranean-style pattern—even with modest lean beef—increased gut microbiota diversity and lowered plasma and urinary TMAO compared with an average American diet. The Mediterranean diet carries the longest evidence base, stretching back to the Seven Countries Study in the late 1950s, and a recent meta-analysis confirms that higher adherence is associated with lower all-cause mortality.

Lifestyle and environment complete the picture. Regular physical activity is reliably linked to lower all-cause and cardiovascular mortality, with the largest gains at moderate-to-intense levels before benefits plateau; athletes show longer telomeres and higher telomerase activity, though this cellular link remains correlational. Smoking cessation markedly reduces recurrent cardiovascular events and death compared with continued smoking, with former heavy smokers in the Framingham Heart Study achieving substantial risk reduction within five years—though residual excess risk persists relative to never-smokers. Sleep follows a U-shaped risk curve: seven to nine hours per night offers the lowest mortality, while short sleepers face a 48% higher risk of coronary heart disease, and adherence to healthy sleep patterns was associated with roughly 4.7 additional years of life in men and 2.4 in women. Environmental exposures weigh heavily too: indirect calculations estimate a loss of 0.7 to 1.6 years of life expectancy per 10 µg/m³ increase in long-term PM2.5 exposure, and US metropolitan data show that a 10 µg/m³ reduction over two decades added about 0.61 years of life expectancy. Noise pollution, climate extremes, and microplastics found in atheromatous plaques raise concern, though direct evidence linking these exposures to reduced human lifespan remains limited.

The review closes with a candid accounting of what remains unknown. Longevity genetics is polygenic and inconsistently replicated across ancestries, with APOE the only locus consistently confirmed across populations; genetic studies remain heavily skewed toward European-ancestry cohorts, limiting generalizability. Epigenetic clocks such as those developed by Hannum and Horvath can quantify biological age from DNA methylation patterns and flag accelerated aging linked to cardiovascular risk, but they are not yet standardized or clinically validated. Clonal hematopoiesis—somatic mutations in blood stem cells—connects acquired genetic damage to inflammation and mortality. Looking ahead, the authors point to artificial intelligence, single-cell sequencing, and machine learning-refined aging clocks as tools that could map cellular aging across tissues and eventually enable precision therapies targeting FOXO3, SIRT1, and mTOR. For now, the practical message is grounded and consistent: heart-healthy diets, regular exercise, smoking cessation, adequate sleep, and cleaner air are the interventions with the strongest evidence—proven for cardiovascular risk reduction, and plausibly, though less conclusively, for longevity itself.

Subject of Research: Cardiovascular health and longevity

Article Title: Cardiovascular health and longevity: where are we?

Article References: Seri, A., Yue, B., Khawaja, M., Tang, W. H. W., Birnbaum, Y., Lavie, C. J., Virani, S. S., Strauss, M., & Krittanawong, C. (2026). Cardiovascular health and longevity: where are we?. Frontiers in Cardiovascular Medicine, 13, Article 1921582. https://doi.org/10.3389/fcvm.2026.1921582

Image Credits: AI Generated

DOI: 10.3389/fcvm.2026.1921582

Keywords: cardiovascular health, longevity, Life's Essential 8, cardiovascular aging, inflammaging, Mediterranean diet, FOXO3, APOE, arterial stiffness, air pollution, sleep health, epigenetic clocks